Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Huntington's disease (HD), an inherited neurodegenerative disorder, results from an abnormal polyglutamine extension in the N-terminal region of the huntingtin protein. This mutation leads to protein aggregation and neurotoxicity. Despite its widespread expression in the brain and body, mutated huntingtin causes selective degeneration of striatal projection neurons. In the present study, we investigate the role of dopamine (DA) in this preferential vulnerability. Using primary cultures of striatal neurons transiently expressing GFP-tagged-exon 1 of mutated huntingtin, we show that low doses of DA (100 microM) act synergistically with mutated huntingtin to activate the proapoptotic transcription factor c-Jun. Surprisingly, DA also increases aggregate formation of mutated huntingtin in all cellular compartments, including neurites, soma, and nuclei. DA-dependent potentiation of c-Jun activation was reversed by ascorbate, a reactive oxygen species (ROS) scavenger, and SP-600125, a selective inhibitor of the c-Jun N-terminal kinase (JNK) pathway. By contrast, DA effects on aggregate formation were reversed by a selective D2 receptor antagonist and reproduced by a D2 agonist. Similarly, striatal neurons from D2 knockout mice showed no effect of DA on aggregate formation. Blocking ROS production, JNK activation, or D2 receptor stimulation significantly reversed DA aggravation of mutated huntingtin-induced striatal death. The combined treatment with the ROS scavenger and D2 antagonist totally reversed DA's effects on mutated huntingtin-induced striatal death. Thus, the present results provide insights into the cellular mechanisms that govern striatal vulnerability in HD and strongly support a dual role of JNK activation and D2 receptor signaling in this process.

[1]  S. W. Davies,et al.  Transgenic Mice in the Study of Polyglutamine Repeat Expansion Diseases , 1998, Brain pathology.

[2]  W. Slikker,et al.  Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum , 1996, Brain Research.

[3]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[4]  M. Chesselet,et al.  Toxicity of Dopamine to Striatal Neurons In Vitro and Potentiation of Cell Death by a Mitochondrial Inhibitor , 1998, Journal of neurochemistry.

[5]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[6]  M. Chesselet,et al.  Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.

[7]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[8]  G. Pearlson,et al.  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[9]  A. Saiardi,et al.  Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors , 1995, Nature.

[10]  D. Sulzer,et al.  Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. , 2001, Human molecular genetics.

[11]  S. Willaime-Morawek,et al.  C-jun N-terminal kinases/c-Jun and p38 pathways cooperate in ceramide-induced neuronal apoptosis , 2003, Neuroscience.

[12]  I. M. Stanford,et al.  Dopamine D2 receptor mediated presynaptic inhibition of striatopallidal GABAA IPSCs in vitro , 2001, Neuropharmacology.

[13]  C. Ross,et al.  Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. , 2003, Human molecular genetics.

[14]  D. Sax,et al.  Factors associated with slow progression in Huntington's disease. , 1991, Archives of neurology.

[15]  Xiantao Wang,et al.  Dopamine Induces Apoptosis through an Oxidation-involved SAPK/JNK Activation Pathway* , 1998, The Journal of Biological Chemistry.

[16]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[17]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[18]  J. Trojanowski,et al.  “Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders , 2000, Annals of the New York Academy of Sciences.

[19]  K. Kieburtz,et al.  Functional decline in Huntington's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[20]  David W. Miller,et al.  Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. , 2003, Brain research. Molecular brain research.

[21]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[22]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[23]  D. Bozyczko‐Coyne,et al.  Targeting the JNK pathway for therapeutic benefit in CNS disease. , 2002, Current drug targets. CNS and neurological disorders.

[24]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[25]  J. Geddes,et al.  6-Hydroxydopamine Injections into the Nigrostriatal Pathway Attenuate Striatal Malonate and 3-Nitropropionic Acid Lesions , 1998, Experimental Neurology.

[26]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[27]  Andreas Matouschek,et al.  Inefficient degradation of truncated polyglutamine proteins by the proteasome , 2004, The EMBO journal.

[28]  J. Aceves,et al.  D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus , 1997, Neuroscience Letters.

[29]  H Li,et al.  Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice , 2001, The Journal of Neuroscience.

[30]  Eugene M. Johnson,et al.  Mixed-lineage kinases: a target for the prevention of neurodegeneration. , 2004, Annual review of pharmacology and toxicology.

[31]  W. Cass.  Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. , 1997, The Journal of pharmacology and experimental therapeutics.

[32]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[33]  J. Marshall,et al.  Activation of MLK2-mediated Signaling Cascades by Polyglutamine-expanded Huntingtin* , 2000, The Journal of Biological Chemistry.

[34]  M. Chesselet,et al.  Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.

[35]  A. Morton,et al.  Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntington’s Disease , 1998, The Journal of Neuroscience.

[36]  Y. Liu.  Expression of Polyglutamine-expanded Huntingtin Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line* , 1998, The Journal of Biological Chemistry.

[37]  A. Carlsson,et al.  In Vivo Autoxidation of Dopamine in Guinea Pig Striatum Increases with Age , 1990, Journal of neurochemistry.

[38]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Maragos,et al.  Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.

[40]  J. Caboche,et al.  Expanded huntingtin activates the C-JUN N TERMINAL KINASE/C-JUN pathway prior to aggregate formation in striatal neurons in culture , 2004, Neuroscience.

[41]  M. Krawczak,et al.  Covariate-dependent age-at-onset distributions for Huntington disease. , 1991, American journal of human genetics.

[42]  T. Sotnikova,et al.  Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Merienne,et al.  Polyglutamine Expansion Induces a Protein-damaging Stress Connecting Heat Shock Protein 70 to the JNK Pathway* , 2003, The Journal of Biological Chemistry.

[44]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.